Strata Critical Medical vs TransMedics
SRTA and TMDX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SRTA and TMDX compare
TransMedics is the larger company, worth 6.5 times as much as Strata Critical Medical ($3.2B against $487M).
On earnings, Strata Critical Medical is cheaper: it trades at 10.8× trailing earnings, against 25.0× for TransMedics.
Strata Critical Medical grew revenue faster over the last twelve months (66.8% versus 28.5% for TransMedics).
TransMedics keeps more of each dollar of sales as profit, with a net margin of 19.9% compared with 15.7% at Strata Critical Medical.
Strata Critical Medical scores higher on the StockData Score (17 against 15 for TransMedics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SRTA | TMDX |
|---|---|---|
| Size and price | ||
| Market cap | $487M | $3.2B |
| Share price | $5.51 | $91.38 |
| Change, 1 year | 8.0% | −23.3% |
| Change, 5 years | −43.0% | 301% |
| Beta (5Y) | 1.63 | 1.34 |
| Employees | 601 | 898 |
| StockData Score | ||
| Total score | 17 (better) | 15 |
| Valuation score | 4 | 5 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 3 | 4 (better) |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 10.8× (better) | 25.0× |
| P/S | 1.9× (better) | 4.4× |
| P/B | 1.7× (better) | 5.8× |
| EV/EBITDA | – | 21.5× |
| P/FCF | – | 70.9× |
| FCF yield | −9.9% | 1.4% (better) |
| Fair value | $8.72 | $129.52 |
| Margin of safety | 36.8% (better) | 29.4% |
| Growth | ||
| Revenue growth (TTM) | 66.8% (better) | 28.5% |
| Revenue growth, 5Y average | 44.6% | 88.2% (better) |
| Net income growth (TTM) | – | 57.4% |
| EPS growth (TTM) | – | 47.8% |
| Profitability | ||
| Gross margin | 20.6% | 58.6% (better) |
| Operating margin | −8.0% | 11.9% (better) |
| Net margin | 15.7% | 19.9% (better) |
| FCF margin | −18.9% | 6.1% (better) |
| Return on equity | 16.0% | 31.9% (better) |
| Return on invested capital | −8.8% | 2622% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.10 (better) |
| Net debt / EBITDA | – | −3.45 |
| Interest coverage | – | 3.5× |
| Current ratio | 2.64 | 4.53 (better) |
| Altman Z-score | 5.67 (better) | 2.84 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 63.0% | 100% |
| Held by insiders | 21.0% | 3.9% |
| Insider net buying, 12 months | −$724K (better) | −$4.2M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.5% | 26.6% |
Go deeper
- SRTA stock overview
- SRTA income statement
- SRTA valuation and score
- TMDX stock overview
- TMDX income statement
- TMDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.